Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs : The HERO study
Copyright © 2023. Published by Elsevier B.V..
BACKGROUND: Objective adherence measures, such as electronic blister pack (BP), for direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment have high accuracy, but their use is limited in real practice settings. We examined the association of self-reported adherence using a visual analogue scale (VAS) with objective BP adherence and sustained virologic response (SVR) among people who inject drugs.
METHODS: We conducted secondary analyses using a subset of participants (N = 493) from the per-protocol sample of the HERO study, a pragmatic randomized trial of HCV treatment interventions that used both VAS and BP to measure adherence to a 12-week sofosbuvir/velpatasvir DAA regimen. Multivariable mixed-effects regression models tested the association of self-report adherence level with longitudinal weekly objective adherence. Multivariable logistic regression tested the association of self-report adherence with SVR.
RESULTS: The average VAS and BP adherences were 95.1 % (SD = 8.9 %) and 76.0 % (16.0 %), respectively, and the proportion of the participants achieving SVR was 92.9 %. The estimated adjusted mean objective adherence was significantly different (-16 %; 95 % CI: -22 %, -11 %, p < .001) between participants with 100 % and <80 % VAS adherence. The likelihood of SVR was significantly lower for those with <80 % VAS adherence [adjusted OR = 0.07; 95 % CI: 0.02, 0.24; p < .001] compared to those with 100 %.
CONCLUSION: Self-reported adherence overestimated objective adherence. However, higher self-report adherence was significantly associated with higher objective adherence. Also, self-reported adherence ≥80 % was significantly associated with SVR. Thus, the self-report measure has utility as a monitoring tool for adherence during DAA treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:123 |
|---|---|
| Enthalten in: |
The International journal on drug policy - 123(2024) vom: 15. Jan., Seite 104288 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lopes, Snehal S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 26.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drugpo.2023.104288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365941514 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365941514 | ||
| 003 | DE-627 | ||
| 005 | 20240127231903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drugpo.2023.104288 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1272.xml |
| 035 | |a (DE-627)NLM365941514 | ||
| 035 | |a (NLM)38103458 | ||
| 035 | |a (PII)S0955-3959(23)00335-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lopes, Snehal S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs |b The HERO study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Objective adherence measures, such as electronic blister pack (BP), for direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment have high accuracy, but their use is limited in real practice settings. We examined the association of self-reported adherence using a visual analogue scale (VAS) with objective BP adherence and sustained virologic response (SVR) among people who inject drugs | ||
| 520 | |a METHODS: We conducted secondary analyses using a subset of participants (N = 493) from the per-protocol sample of the HERO study, a pragmatic randomized trial of HCV treatment interventions that used both VAS and BP to measure adherence to a 12-week sofosbuvir/velpatasvir DAA regimen. Multivariable mixed-effects regression models tested the association of self-report adherence level with longitudinal weekly objective adherence. Multivariable logistic regression tested the association of self-report adherence with SVR | ||
| 520 | |a RESULTS: The average VAS and BP adherences were 95.1 % (SD = 8.9 %) and 76.0 % (16.0 %), respectively, and the proportion of the participants achieving SVR was 92.9 %. The estimated adjusted mean objective adherence was significantly different (-16 %; 95 % CI: -22 %, -11 %, p < .001) between participants with 100 % and <80 % VAS adherence. The likelihood of SVR was significantly lower for those with <80 % VAS adherence [adjusted OR = 0.07; 95 % CI: 0.02, 0.24; p < .001] compared to those with 100 % | ||
| 520 | |a CONCLUSION: Self-reported adherence overestimated objective adherence. However, higher self-report adherence was significantly associated with higher objective adherence. Also, self-reported adherence ≥80 % was significantly associated with SVR. Thus, the self-report measure has utility as a monitoring tool for adherence during DAA treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pragmatic Clinical Trial | |
| 650 | 4 | |a Direct-acting antiviral medication | |
| 650 | 4 | |a Electronic blister pack adherence | |
| 650 | 4 | |a Hepatitis C | |
| 650 | 4 | |a People who inject drugs | |
| 650 | 4 | |a Self-report adherence | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Pericot-Valverde, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Arnsten, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Lum, Paula J |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Lynn E |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Shruti H |e verfasserin |4 aut | |
| 700 | 1 | |a Tsui, Judith I |e verfasserin |4 aut | |
| 700 | 1 | |a Feinberg, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Arthur Y |e verfasserin |4 aut | |
| 700 | 1 | |a Norton, Brianna L |e verfasserin |4 aut | |
| 700 | 1 | |a Page, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Murray-Krezan, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Moschella, Phillip |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, Moonseong |e verfasserin |4 aut | |
| 700 | 1 | |a Litwin, Alain H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The International journal on drug policy |d 1996 |g 123(2024) vom: 15. Jan., Seite 104288 |w (DE-627)NLM089798821 |x 1873-4758 |7 nnns |
| 773 | 1 | 8 | |g volume:123 |g year:2024 |g day:15 |g month:01 |g pages:104288 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drugpo.2023.104288 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 123 |j 2024 |b 15 |c 01 |h 104288 | ||